lyt-200
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04666688)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Galectin-9INHIBITOR
LGALS9 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05829226 | Phase 1 | Dec 12, 2022 | PureTech |
| NCT04666688 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2020 | PureTech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PureTech | For profit | 2 | 2 | 2 | 2020 |
1 organizations
Page 1 / 1